Figure 5.

PRC1 promotes the multi-drug resistance of ovarian cancer cells in vitro. (A) Expression of PRC1 evaluated by immunohistochemical staining in tissues of patients with second-line platinum-based chemotherapy. (B) PRC1 mRNA expression in patients with information of second-line platinum-based chemotherpay. (C-F) MTT assay was performed to evaluate the changes of IC₅₀ of cisplatin, taxol and LPD in PRC1 knockdown and overexpression cells. (G and H) Western blot and the corresponding densitometric analysis were used to evaluate the changes in the protein levels in the A2780 and SKOV3 cells with PRC1 knockdown. ^*P<0.05 and ^**P<0.01. PRC1, protein regulator of cytokinesis-1; LPD, pegylated liposomal doxorubicin; BRCA1, breast cancer 1; PARP1, poly(ADP-ribose) polymerase 1; AURKB, Aurora B kinase.